Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: A meta-analysis of randomized controlled trials - Li, G; Crowley, M J; Tang, H (Diabetes Care, 2019)
et al.